160.93
price up icon4.11%   6.19
after-market After Hours: 160.93
loading
Beigene Ltd Adr stock is traded at $160.93, with a volume of 119.30K. It is up +4.11% in the last 24 hours and up +3.20% over the past month. BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
See More
Previous Close:
$154.74
Open:
$156.12
24h Volume:
119.30K
Market Cap:
$16.70B
Revenue:
$2.76B
Net Income/Loss:
$-784.43M
P/E Ratio:
-9.6378
EPS:
-16.6978
Net Cash Flow:
$-1.57B
1W Performance:
+9.03%
1M Performance:
+3.20%
6M Performance:
+2.86%
1Y Performance:
-18.43%
1D Range:
Value
$155.30
$161.24
52W Range:
Value
$126.97
$225.23

Beigene Ltd Adr Stock (BGNE) Company Profile

Name
Name
Beigene Ltd Adr
Name
Phone
13459494123
Name
Address
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Name
Employee
10,000
Name
Twitter
@beigeneusa
Name
Next Earnings Date
2024-07-31
Name
Latest SEC Filings
Name
BGNE's Discussions on Twitter

Beigene Ltd Adr Stock (BGNE) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-06-24 Resumed JP Morgan Overweight
Sep-12-23 Initiated Macquarie Outperform
Aug-17-23 Initiated Jefferies Buy
Jul-17-23 Initiated Citigroup Buy
Jun-30-23 Downgrade Bernstein Outperform → Mkt Perform
Jan-12-23 Initiated Daiwa Securities Buy
Oct-13-22 Upgrade Guggenheim Neutral → Buy
Oct-13-22 Upgrade SVB Leerink Mkt Perform → Outperform
Aug-09-22 Resumed JP Morgan Overweight
Mar-17-22 Downgrade SVB Leerink Outperform → Mkt Perform
Feb-07-22 Initiated Deutsche Bank Buy
Oct-12-21 Initiated Bernstein Outperform
Oct-06-21 Upgrade CLSA Underperform → Buy
Mar-08-21 Initiated China Renaissance Buy
Mar-01-21 Downgrade CLSA Outperform → Underperform
Nov-09-20 Downgrade Ladenburg Thalmann Buy → Neutral
Nov-06-20 Downgrade Maxim Group Buy → Hold
Nov-06-20 Downgrade Piper Sandler Neutral → Underweight
Jul-10-20 Downgrade CLSA Buy → Outperform
Mar-13-20 Upgrade Macquarie Underperform → Neutral
Feb-18-20 Resumed Goldman Buy
Jan-17-20 Upgrade CLSA Outperform → Buy
Jan-17-20 Resumed Morgan Stanley Overweight
Dec-16-19 Downgrade Guggenheim Buy → Neutral
Dec-16-19 Downgrade Piper Jaffray Overweight → Neutral
Nov-19-19 Downgrade UBS Buy → Neutral
Nov-13-19 Downgrade CLSA Buy → Outperform
Nov-04-19 Reiterated Maxim Group Buy
Jun-04-19 Initiated Bernstein Outperform
May-10-19 Upgrade CLSA Outperform → Buy
Mar-15-19 Initiated BofA/Merrill Buy
Jan-04-19 Downgrade CLSA Buy → Outperform
Nov-21-18 Initiated JP Morgan Overweight
Sep-25-18 Initiated Leerink Partners Outperform
May-17-18 Reiterated Maxim Group Buy
View All

Beigene Ltd Adr Stock (BGNE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$85.31
price up icon 1.57%
$27.80
price up icon 0.22%
$86.13
price up icon 0.78%
$461.01
price down icon 2.16%
$235.59
price down icon 1.05%
Cap:     |  Volume (24h):